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Abstract.  A cosmid (cos pUK0322) harboring  the 
complete human urokinase-type plasminogen activator 
(u-PA)  gene and Geneticin resistance as a  selectable 
marker was isolated from a human genomic library 
and characterized.  After transfection of cos pUK0322 
into mouse L  cells and selection, several plasminogen 
activator (PA)-expressing clones were obtained and 
one (L~) was chosen for additional study. The PA ex- 
pressed was identical to human pro-u-PA in enzy- 
matic, electrophoretic, and antigenic properties.  The 
expression of PA was stable over 50 population dou- 
blings.  The regulation of the transfected gene was 
studied by treatment of the cells with various hor- 
mones and other effectors. Expression of PA activity 
was inhibited fivefold by dexamethasone and stimu- 
lated two- to threefold by agonists of the adenylate cy- 
clase dependent pathway of signal transduction,  such 
as dibutyryl cyclic AMP and cholera and pertussis 
toxins.  The modulation of PA activity was associated 
with corresponding changes in mRNA steady-state lev- 
els.  The phenotypic changes associated with pro-u-PA 
expression were analyzed in vitro by degradation of 
3H-labeled extracellular matrix  (ECM),  invasion of a 
matrigel basement membrane analogue,  and by light 
and electron microscopy. I~r~ cells and reference HT- 
1080 fibrosarcoma cells, in contrast to control L~o 
cells transfected with the neomycin resistance gene, 
degraded the ECM and invaded the matrigel basement 
membrane.  Matrix degradation correlated with the 
modulation of pro-u-PA gene expression as it was in- 
hibited by dexamethasone and promoted by dibutyryl 
cyclic AMP. Inhibition of PA or plasmin using anti- 
u-PA IgG or aprotinin prevented ECM degradation and 
invasion.  These results demonstrate that u-PA expres- 
sion alon~ is sufficient to confer to a cell an ex- 
perimental  invasive phenotype. 
p 
LASMINOGEN activators  (PA)  j are highly specific ser- 
ine proteases that convert plasminogen  into the tryp- 
sin-like enzyme plasmin (Astrup,  1978). PA-mediated 
plasmin  formation  leads to  fibrin  degradation  and  to  ex- 
tracellular matrix (ECM) remodeling in the course of mor- 
phogenetic events like ontogeny and neoplasmic growth (for 
reviews see Blasi et al.,  1987; Dane et al.,  1985; Saksela, 
1985). There are two genetically distinct PAs: tissue-type PA 
and urokinase-type PA (u-PA). Of these, u-PA has been im- 
plicated in contributing  to the mechanism of invasive growth 
of tumors (for review see Dane et al., 1985). u-PA also ap- 
pears to play an important  role in metastasis formation:  anti- 
bodies to u-PA inhibited  metastasis  of Hep3 human epider- 
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moid carcinoma cells in the chick embryo (Ossowski  and 
Reich,  1983)  and  such  antibodies also decreased signifi- 
cantly the number of pulmonary metastases  of B16 mouse 
melanoma cells in mice (Hearing et al.,  1988). 
Plasmin  activates  latent  collagenase  (Mignatti  et  al., 
1986), leading to degradation  of collagen constituents  of the 
ECM. Other enzymes such as elastase and various cathep- 
sins are also believed to play a role in ECM degradation  (for 
review see Str/iuli et al.,  1980). Because of the complexity 
of these proteolytic events,  it is difficult  to assess the in- 
dividual  contributions of the various enzymes in wild-type 
cells. To study the phenotypic change caused by the expres- 
sion of a single gene, we have transfected a cosmid contain- 
ing the natural  human  pro-u-PA gene into  mouse L cells, 
which do not naturally express PA. We demonstrate that the 
gene remains  sensitive to regulatory  mechanisms that have 
previously been shown to be effective at its natural locus. The 
effects of u-PA expression and regulation in u-PA-transfected 
I~,A cells on the degradation  of the ECM and on basement 
membrane invasion were studied using biochemical and mor- 
phological  analysis. 
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Materials 
Dexamethasone, cholera toxin, dibutyryl cyclic AMP, Geneticin, ribonu- 
clease, proteinase K, bovine trypsin (type XI), and salmon testes DNA (type 
HI) were from Sigma Chemical Co. (St. Louis, MO); plasminogen-rich bo- 
vine fibrinogen v,  as from Opopharma (Ziirich, Switzerland); pertussis toxin 
was from List Biological Laboratories (Campbell, CA); phenol, uranyl ace- 
tate,  lead citrate, and methylene blue/azur II solution were from Merck 
(Darmstadt, Federal Republic of Germany); osmium tetroxide was from 
Elmis  (Carouge,  Switzerland);  in  vitro-packaging system from Genofit 
(Geneva, Switzerland); restriction enzymes were from Boehringer Mann- 
heim (Rotkreuz,  Switzerland); bacterial  collagenase (type CLSPA) was 
from Worthington Biochemical Corp.  (Freehold, NJ); Gene Screen Plus 
membranes were from new England Nuclear (Boston, MA); cacodylate, 
Epon 812 and glutaraldehyde were from Fluka AG (Buchs, Switzerland); 
and tissue culture 100-mm-diam dishes and 24-well plates were from Gibco 
Laboratories (Basel, Switzerland). The pSV2neo plasmid was kindly pro- 
vided by Dr. P. Cerutti (Swiss Institute for Experimental Cancer Research, 
Epalinges, Switzerland). Rabbit anti-human u-PA serum was a girl of Dr. 
J. Hanert (Hematology Department, Centre Hospitalier Universitaire Vau- 
dois, Lausanne, Switzerland). Mouse L  cells were obtained from Dr. J. 
Maryansld (Ludwig Institute for Cancer Research, Epalinges, Switzerland). 
Other materials were as previously described (Cajot et al.,  1986a,b). 
PA Activity Assay 
PA activity of tumor cell-conditioned media was assayed using the 125I- 
fibrin plate method (Unkeless ct al.,  1973).  All activities are expressed in 
international units by comparison with a standard curve of u-PA calibrated 
against the international reference preparation of human u-PA (1 IU corre- 
sponds to 2 ng two-chain active u-PA enzyme). Zymographic analysis of 
PA was performed as previously described (Heussen and Dowdle, 1980): 
50-/~1 samples of conditioned media were subjected to SDS-10%  PAGE 
(Laemmli, 1970).  Gel slabs, which contained 2.5 mg/ml of copolymerized 
plasminogen-rich bovine fibrinogen, were incubated for 1 h in 2.5% Triton 
X-100 to allow protein renaturation and subsequently incubated in 0.1 M 
glycine/NaOH (pH 8.3).  Staining of the gels with amido black revealed 
white lysis zones against the undigested blue background. 
Immunoprecipitation 
Conditioned medium was mixed 1:1 (vol/vol) with anti-human u-PA (dilu- 
tion 1:500)  or control nonimmune rabbit serum and incubated for 2 h at 
37°C and for 18 h at 4°C. Antigen-antibody complexes were precipitated 
by  addition  of  150  /tl  of  cellulose  suspensions  coated  with  donkey 
anti-rabbit IgG to 300/tl of the above mixture followed by centrifugation 
at 5,000 g for 5 min. Supernatants were recovered and analyzed for the pres- 
ence of residual PA activity. 
Diisopropylfluorophosphate (DFP) Sensitivity Assay 
DFP sensitivity of zymographic activity was investigated as previously de- 
scribed (Vassalli et al., 1984).  Samples were incubated for 1 h at 37°C with 
25 mIU/ml of plasmin, and the reaction was terminated by addition of 200 
U/ml of aprotinin. Samples were further incubated for 1 h at 37°C with 27 
mM DFP and subjected to zymographic analysis. 
Cell Culture 
Cells were seeded at a density of 4  x  106 into 100-mm-diam tissue culture 
dishes and grown for 36 h in 15 ml DME supplemented with 10%  FCS. 
Subsequently, the medium was removed and cells washed twice with DME. 
Cells were then maintained under serum-free conditions in 8 ml DME con- 
taining 0.1% BSA. To modulate gene expression of u-PA the following com- 
pounds were added to the culture medium: dexamethasone (500 nM), per- 
tussis toxin (5 nM), cholera toxin (50 riM), and dibutyryl cyclic AMP (1 
mM).  Dexamethasone was prepared in 50%  ethanol stock solution. All 
other drugs were prepared in DME containing 0.1%  BSA and stored at 
-80°C until further use. After 24 h, the conditioned media were harvested, 
centrifuged for 5 min at 3,000 g to remove cellular debris, and stored at 
-80°C until used. PA activities measured in conditioned media were ex- 
pressed in IU per 106 cells. Cell extracts were prepared by plating cells as 
described above and growing for 36 h. Confluent cultures were then washed 
twice with serum-free DME followed by incubation in  10 ml lysis buffer 
(1% SDS, 50 mM imidazole-HCl (pH 7.35),  140 mM NaCI) per 100-mm- 
diam dish for 15 min at 20°C. 
Molecular Cloning and Characterization  of a u-PA 
cDNA Clone and the u-PA Gene 
~UK0321  was isolated from a  eDNA library generated in kgtl0 by the 
method of Guebler and Hoffman (1983) from mRNA isolated and enriched 
by sucrose gradient centrifugation from human HT-1080 fibrnsarcoma cells. 
Mixed oligonucleotide probes corresponding to a  u-PA eDNA sequence 
(Giinzler et al.,  1982) were synthesized and used for screening (Maniatis 
et al., 1982). The insert of ?~UK0321 was subcloned into pUC8 (Vieira and 
Messing, 1982) giving rise to pUK0321,  sequenced (Maxam and Gilbert, 
1977),  and found to harbor a  1,023-bp  fragment of human u-PA cDNA, 
reaching from the bp 727 to  1,750, described by Verde et al.  (1984).  cos 
pUK0322 was isolated from a human cosmid library (Grosveld et al., 1982) 
by colony hybridization (Grunstein and  Hogness,  1975) using the nick- 
translated 1,023-bp Eco RI insert ofpUK0321. Restriction mapping was per- 
formed by the partial digestion method of Smith and Birnstiel (1976) using 
the indirect labeling method described by Rackwitz et al. (1985).  Fragments 
were separated by field inversion electrophoresis as described (Carle et al., 
1986). 
Isolation of  Plasmid, Cosmid, and Genomic DNA 
High molecular weight genomic DNA was prepared from cultured cells as 
described (Reymond, 1987) with the following modifications: the extracted 
DNA was subjected to an additional step of RNase and proteinase K diges- 
tion, phenol-chloroform  extracted, ethanol precipitated, and resuspended in 
NaCI/Tris/EDTA (100:10:1) according to standard procedures (Maniatis et 
al., 1982).  Plasmid DNA was prepared using the alkaline lysis method fol- 
lowed by CsCl/ethidium bromide equilibrium centrifugation (Birnboim and 
Doly, 1979).  Cosmid DNA was packaged in vitro using a commercial kit 
(Genofit) following the manufacturer's instructions. Escherichia coli HB101 
cells were infected with cosmid DNA-containing phages as described by 
Becker and Gold (1975) and used for cosmid DNA preparation as described 
above for the preparation of plasmid DNA. 
Southern Blot Analysis 
For Southern blot anlaysis (Southern,  1975) 10 #g of genomic DNA and 
1/~g of  cos pUK0322 DNA were digested with restriction enzymes, electro- 
phoresed through a 0.8% agarose gel slab, and transferred to nitrocellulose 
filter paper. The filters were prehybridized at 65°C for 2 h in 4x  SSC, 20 
mM  phosphate buffer, 0.017%  Denhardt's solution,  0.1%  SDS,  0.005% 
pyrnphosphate, and 0.0125 % carrier DNA and subsequently hybridized for 
20 h at 65°C in the presence of 107 cpm of a nick-translated Eco RI-Hind 
III (60"/-bp) fragment of pUK0321  (human urokinase eDNA clone). The 
filter was washed twice for 30 min at 65°C in 500 ml, each wash, of succes- 
sively decreasing salt solutions: 2x  SSC, 0.05%  SDS, 0.01% pyrophos- 
phate; lx SSC, 0.05%  SDS, 0.01% pyrophosphate; 0.1x SSC, 0.05%  SDS, 
0.01% pyrophosphate. 
Transfections 
Mouse L cells (Sanford et al., 1948) were transfected with cosmid pUK0322 
using the calcium phosphate coprecipitation method as previously described 
(Graham and Van der Eb, 1973) as modified by Wigler et al. (1979).  5 ~g 
of circular cosmid DNA was coprecipitated with 30 ~g of carrier salmon 
testes DNA and added to a 25-cm  2 tissue culture flask seeded 24 h earlier 
with 106 cells. Control transfections were performed in parallel with either 
5 tLg of circular pSV2neo DNA plus carrier DNA or carrier DNA alone. 
DNA-containing media were removed after an 18-h incubation at 37°C, and 
transfected cells were maintained for a 48-h culture in fresh medium. After 
trypsinization, 106 cells were transferred to 100-mm-diam dishes and cul- 
tured in 15 ml of DME,  10%  FCS containing 1 mg/rni of Geneticin. The 
selection medium was changed after 8 d, and drug-resistant clones were iso- 
lated with the aid of cloning cylinders after 15 d. 
Determination of  Gene Copy Number 
To quantitate the copy number of the transfected gene, 10 t~g of Lup, DNA 
was digested with Sma I and subjected to Southern blot analysis using hu- 
man u-PA cDNA (pUK0321)  as a probe. Serial dilutions of cos pUK0322 
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lyzed under identical conditions. The u-PA gene copy number of transfected 
cells was calibrated by comparison of the LupA DNA hybridization signal 
with that of pUK0322 dilutions. 
Northern Blot Analysis 
RNA was isolated as previously described (Medcalf et al., 1986) and sub- 
jected to  Northern analysis using the specifications of Thomas (1980). 
Agarose gel (0.9%) electrophoresis of mRNA was performed in the pres- 
ence of 20%  formaldehyde and 300 ng/ml ethidium bromide. After elec- 
trophoresis, gels were photographed using a UV transilluminator (260 nm) 
to localize ribosomal RNA bands and to assess lane variations in RNA load- 
ing. Northern blot transfer was performed as described by Thomas (1980), 
except the Gene Screen Plus membrane was used. Hybridization conditions 
and processing of filters were as previously described (Medcalf  et al., 1988). 
Densitometric analysis of mRNA signals on autoradiograms was performed 
using a densitometer (Ultroscan XL model 2222; LKB-Pharmacia, Diiben- 
doff, Switzerland). All calculations were expressed relative to an arbitrary 
value of one assigned to the signal obtained with untreated LupA cell ex- 
tract. 
ECM Degradation Assay 
Preparation  of [3H]proline biosynthetically labeled  ECM  from  R22  rat 
smooth muscle cells was performed as described (Jones and DeClerck, 
1980).  Matrix degradation was initiated by plating (at day 0) 50,000  cells 
per 13-mm-diam well in 500/~1  DME containing 10%  FCS. Media were 
changed daily and supernatants were counted for radioactivity in a scintilla- 
tion counter.  Matrix degradation was modulated by addition of various 
agents in cell culture medium at day 0 and daily addition of fresh drug up 
to day 4  of the assay (for morphological characterization the assay was 
performed up to day 7). Final drug concentrations were:  10 p,g/ml protein 
A-Sepharose-purified IgG (preimmune and anti-u-PA); 200 U/ml aproti- 
nin, 500 nM dexamethasone, and l  mM cyclic AME Enzymatic degrada- 
tion of residual matrix after tumor cell culture was performed by incubating 
R22 rat smooth muscle cell matrix in presence or absence of tumor cells 
for 4 d. Tumor cells were then eliminated by incubation in 25 mM NI-hOH 
for 20 min at 20°C and the residual matrix was washed three times with 
1 ml DME. Enzymes were then added sequentially (trypsin followed by col- 
lagenase) at  100 /zg/ml  final concentration, and each digestion was per- 
formed at 37°C for 48 h. 
Invasion Assay with Reconstituted 
Basement Membrane 
Invasion assay using matrigel-coated nuclepore filters was performed as de- 
scribed (Albini et al., 1987).  Nuclepore filters (13 mm filter diameter; 8/zm 
pore diameter) were coated with  100 #1 of various dilutions of basement 
membrane matrigel at 10 mg/ml and dried at 37°C for 2 h. Blind well Boy- 
den chambers were filled with 200 t~l DME, 10% FCS in the lower compart- 
ment and coated filters mounted in the chamber. The upper compartment 
was filled with 800/zl of cell suspension at 300,000  cells/ml in DME, 10% 
FCS. Where stated, aprotinin was added to the cell suspension at 200 U/ml. 
The wells were incubated for 12 h at 37°C in 5% CO2. The filters were 
then removed, fixed 10 min in 30% methanol, 7% acetic acid solution, and 
stained for 20 rain in 20%  Giemsa solution. All material from the upper 
surface of the filter was carefully removed by scraping with a cotton tip, and 
invasive cells adhering to the lower surface of  the filter were counted by light 
microscopy (250x)  at randomly chosen areas (each sample was assayed 
using quadruplicate filters and filters were counted at four areas). Results 
are  expressed as  cell  number  per visual  field  (one  microscopical field 
represents 1/200 of the filter surface). 
Preparation  for Light and Electron Microscopy 
Cells cultured onto the R22 radiolabeled matrix in 24-well tissue culture 
plates were prefixed for 1 h at room temperature and then fixed at 4°C with 
2.5% cacodylate-bulfered (0.1 M, pH 7.35) glutaraldehyde at days 1, 4, and 
7. After extensive washing with 0.1  M cacodylate, cultures were fixed for 
! h at room temperature with 2% osmium tetroxide in 0.1  M cacodylate, 
dehydrated, and embedded in Epon 812. Thin sections were contrasted with 
uranyl acetate and lead citrate. Control, thick thin sections for light micros- 
copy were stained with methylene blue-azur II solution. 
Results 
Expression of  Human Pro-u-PA by Mouse L Cells 
A  series of ten Geneticin-resistant colonies isolated after 
transfection with cos pUK0322 or pSV2neo were assayed for 
the presence of PA activity in culture supernatants using the 
~25I-fibrin method. All cos pUK0322 transfectants expressed 
PA  activity  (ten  clones  assayed;  0.8-4.5  IU/ml  range), 
whereas no activity was detected in the conditioned media 
of  control pSV2neo transfected cells (five clones). From each 
of these transfectants (pUK0322 and pSVneo), representative 
clones were selected and established as cell lines (Lu,^ and 
L~, respectively) for further characterization. 
The PA expressed by L,A cells was shown by zymogra- 
phy to comigrate with human but not with mouse u-PA (Fig. 
1, lanes 1-3). A feeble band, observed at a position corre- 
sponding to 110 kD, represents a complex between u-PA and 
a specific PA inhibitor that is found in the conditioned medi- 
um of several cells producing PA and PA inhibitor (Cajot et 
al., 1986a;  Levin, 1983; Philips et al., 1984).  The 33- and 
29-kD species represent degradation products of human and 
mouse high relative molecular mass u-PA,  respectively. PA 
activity was not detected in conditioned medium derived 
from either L~ or parental L cells (Fig.  1, lanes 4 and 5). 
Cell extracts were also analyzed for PA activity. A  54-kD 
band was associated with L~pA cells, whereas no PA-related 
activity was observed in L~ cell extract (Fig. 1, lanes 6 and 
7).  To establish the immunological identity of the PA ex- 
pressed, conditioned medium was immunoprecipitated with 
anti-human u-PA or control rabbit nonimmune serum, and 
the supernatants were  subjected to zymographic analysis. 
The results demonstrate that the 54-kD band released by 
LupA cells is immunologically related to human u-PA (Fig. 
2,  lanes 1-3). Treatment of Lup^ cells with dexamethasone 
or dibutyryl cyclic AMP resulted in modulation of  the 54-kD 
band.  As  shown  in  lanes  4-6, dexamethasone inhibited, 
whereas dibutyryl cyclic AMP stimulated, u-PA expression 
compared with untreated cells. These results also demon- 
strate that essentially the 54-kD PA species is affected by 
these drugs, while the ll0-kD PA-PA inhibitor complex ap- 
pears  unaltered.  DFP  sensitivity of PA expressed by L~ 
cells is shown in Fig. 3. Conditioned medium-derived u-PA 
was largely resistant to DFP (lanes 3 and 4). Under identical 
experimental conditions, urinary u-PA activity was totally 
quenched (lanes I and 2). After activation by limited plasmin 
cleavage, LpA-secreted PA became accessible to DFP inhi- 
bition (lanes 5 and 6). Hence u-PA was secreted from L,P, 
cells as a DFP-resistant proenzyme (pro-u-PA), which upon 
limited plasmin treatment has been shown to be converted to 
the active two-chain form (Nielson et al., 1982; Wun et al., 
1982). 
Restriction Mapping of Cosmid pUK 0322 
and Southern Blot Analysis of  Human u-PA DNA 
Sequences in LueA Cells 
The  restriction map  (Fig.  4)  demonstrates that pUK0322 
embodies the structural gene of pro-u-PA including at least 
23 kb of 5' flanking sequences, some of which were previ- 
ously described (Riccio et al., 1985).  The map agrees with 
the published data within an acceptable limit of error, except 
for the presence of an additional Eco RI site in map position 
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expressed by transfected mouse L cells. Samples were electropho- 
retically  separated in  10%  SDS-polyacrylamide  gels containing 
2.5  mg/ml copolymerized plasminogen-rich fibrinogen, and PA- 
related fibrinolytic activity was detected by zymographic analysis. 
(Lane 1) Human urine; (lane 2) murine urine; (lanes 3-5) condi- 
tioned media of ~,  L,o, and parental L cells, respectively; and 
(lanes 6 and 7) cell extracts of ~r~ and L~o, respectively. 
-9.3 kb, which may represent the site of a polymorphism. 
At the 3' end of the gene, pUK0322 contains at least 12 kb 
of flanking sequences. 
Southern blot analysis of pUK0322 is shown in Fig. 5 after 
cosmid DNA digestion with Sma I, Eco RI,  Bam HI, and 
Pst I (lanes 1-4, respectively) followed by hybridization of 
digestion  fragments to  a  nick-translated human  urokinase 
cDNA probe. The presence of human u-PA-specific DNA 
sequences in  L~,, cells is demonstrated as a  6.8-kb Sma I 
fragment (lane  6);  no hybridization signal  is  observed in 
L~ control cells (lane  7).  The genome of this clonal line 
was shown to contain two copies of the human u-PA gene by 
calibration  of  the  hybridization  signal  obtained  for  L,A 
genomic DNA against serial dilutions of pUK0322 contain- 
ing known copy numbers of the u-PA gene. 
Modulation of  Human Pro-u-PA Gene Expression in 
Mouse L Cells 
L~,, cells were treated with various drugs known to modu- 
late u-PA gene expression, and the conditioned media were 
assayed for PA activity. As shown in Fig. 6, dexamethasone 
suppressed, whereas agonists of the adenylate-cyclase path- 
way (dibutyryl cyclic AMP, cholera toxin, and pertussis toxin) 
induced, an increase of PA activity. Zymographic analysis of 
Figure 2. Immunological characterization (lanes 1-3) and regula- 
tion (lanes 4-6) of u-PA expressed by I_~ cells. L~p^-conditioned 
media were analyzed by zymography. Immunosupernatants of L,pA 
conditioned medium obtained after incubation with preimmune se- 
rum (lane 1); anti-human  u-PA serum (lane 2);  or buffer alone 
(lane 3) followed  by immunoprecipitation  of antibody-antigen com- 
plexes. I~pA cells treated with culture medium alone (lane 4); 500 
nM Dex (lane 5); or 1 mM dibutyryl cyclic AMP (lane 6). 50-td 
aliquots of conditioned media were loaded at a dilution of 1:5 for 
lanes 1-3. For semiquantitative estimation of PA activity, samples 
were corrected for cell number and represent the conditioned media 
corresponding to 5  x  1@ cells/ml. 
Figure 3. DFP treatment of pro-u-PA.  Samples were subjected to 
sequential treatment  with plasmin and  DFP as indicated in the 
figure: (+) treated; (-) untreated. (Lanes I and 2) Human urine- 
derived u-PA; (lanes 3-6)  ~pA-derived u-PA. 
conditioned medium (Fig. 2) furthermore demonstrated that 
only the 54-kD human u-PA but not the 48-kD mouse u-PA 
was regulated. These results were corroborated by Northern 
blot analysis (Fig. 7 a). Densitometric analysis of the auto- 
radiograms (Fig. 7 b) indicated that dexamethasone decreased 
human uPA mRNA steady state levels by 50%, whereas cy- 
clic AMP, cholera toxin, and pertussis toxin induced a two- 
to threefold increase. 
ECM Degradation by LueA Cells 
Lu,, cells degraded [3H]proline-labeled rat smooth muscle 
ECM as monitored by the release of solubilized degradation 
products in cell culture supernatants (Fig. 8 A). These cells 
mediated matrix degradation as efficiently as human fibro- 
sarcoma HT-1080 cells. L,o control cells showed no effect. 
Matrix degradation assays were also performed over a  7-d 
period using L~, as well as control L~ and parental L cells. 
These experiments confirmed the ability of Lu,^ cells to de- 
grade ECM, whereas both L~o or parental L cells exhibited 
only weak effects (<5 % of LP, degradation). The measure- 
ment of fibrinolytic activity in cell culture supernatants (Fig. 
8  b)  demonstrated  that  the  secretion of u-PA by Lu~A and 
HT-1080 cells correlated with matrix degradation. The cell 
counts obtained for HT-1080,  L,,, and Ln~o cells during the 
assay period are shown in Fig. 8 c. Hence the difference in 
the  degradation  potential  observed between  Lu,,  and  L~ 
cells was not due to a difference in cell numbers. 
In the presence of anti-u-PA IgG, ECM degradation was 
inhibited  by  80%  when  compared  with  incubation  with 
nonimmune IgG  (Fig.  9).  Addition of aprotinin,  a  potent 
plasmin inhibitor,  likewise inhibited degradation.  Modula- 
tion of u-PA expression by various agents also influenced the 
ECM degradation: dexamethasone inhibited >50%, where- 
as cyclic AMP led to a 40% increase in matrix solubilization. 
Morphological Analysis of Cell-Matrix Interaction 
Fig.  10 illustrates the changes in morphology of R22 matrix 
associated with the coincubation of L~o (a and b) or L,pA (c 
and d) transfectants (a and c are taken at day 1; b and d at 
day 7). There was evidence of cell proliferation of both cell 
types over the 4-d culture period, as already shown by cell 
count determinations (see Fig. 8 c). Both types of transfec- 
tants appeared to adhere equally to the matrix layer, by direct 
contacts or by multiple cytoplasmic extensions. By compar- 
ing Fig. 10, a with b or c with d, it is seen that major changes 
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vector DNA (cos). The different restriction sites of the cosmid are indicated as follows:  A, Acc I; B, Bam HI; E, Eco RI; H, Hind III; 
Hp, Hpa I; S,  Sca I; and X, Xho I. 
in matrix density occur over the coincubation period and that 
alterations, especially a loss of density, are more pronounced 
with  L~,,- than  with  L~o-transfected cells. 
Fig.  11  shows  at  the  ultrastructural  level  a  detailed  se- 
quence analysis of L~o, L,,,  as well as HT-1080 cells coin- 
cubated on the R22 matrix.  Fig.  11, a-c, illustrates at days 
1, 4, and 7, respectively, the interactions of human fibrosar- 
coma HT-1080 cells with the heterogeneous  constituents  of 
the matrix.  Numerous fine cytoplasmic extensions maintain 
close  contacts  (focal  or  extended)  with  the  matrix,  which 
itself  shows  heterogeneous  electron  densities  (very  dense 
amorphous as well as fibrillar materials) and irregular bor- 
ders.  With time, the loss of matrix density appears to affect 
mostly the compact amorphous  material  (Fig.  11,  cf. a-c) 
making  the  fibrillar  constituents  more  apparent.  This  se- 
quence  of events  is  quite  comparable  with  respect  to  L,p, 
cells (Fig.  11, g-i) whereas,  for L~  cells,  the dense amor- 
phous material is present throughout the coincubation period 
(Fig.  11, d-f).  Irregular  matrix borders,  focal or extended 
areas of adhesion have been observed for the three types of 
cell populations:  the two transfectants and the reference HT- 
1080  line. 
Biochemical Analysis of  Residual ECM after 
Tumor Cell Coculture 
To demonstrate which matrix constituents were degraded by 
L~p, cells,  R22  smooth  muscle cell matrix  which  had been 
incubated 4  d  in absence of cells or in presence of l_~,, and 
Ln~o cells  were  used  for  enzyme digestion  experiments  as 
shown  in Fig.  12.  Trypsin digestion of the  residual  matrix 
obtained  after L~,,  cell culture demonstrates  a  25 %  loss of 
trypsin-sensitive material compared with the control  100% 
degradation obtained with the intact ECM.  No alteration  in 
Figure 5. Southern blot analysis of L,~o and Lur~ genomic DNA as 
well as cos pUK0322  DNA.  1 #g of cosmid DNA or  10 #g of 
genomic DNA was digested with the restriction enzymes indicated 
below, electrophoresed through 0.8%  agarose, transferred to nitro- 
cellulose,  and hybridized with the nick-translated 0.6-kb Eco RI- 
Hind III fragment of pUK0321.  (Lanes 1-4) cos pUK0322, digested 
with Sma I, Eco RI, Bam HI, and Pst I, respectively; (lane 5) DNA 
size standard;  (lanes 6 and  7) Sma I-digested genomic DNA de- 
rived from pUK0322- or pSVneo-transfected L cells, respectively. 
Figure 6.  Modulation  of human  urokinase  gene  expression  in 
mouse L cells. L~pA ceils were treated with various drugs, and the 
resulting  conditioned  media were assayed  for PA activity using 
n~I-fibrin plates.  Drug concentrations:  dexamethasone (500 nM); 
dibutyryl cyclic AMP (1 mM); cholera toxin (50 nM); and pertussis 
toxin (5 nM). 
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migrate through a  25-/*g matrigel barrier.  At a  higher con- 
centration  (100/,g/filter),  no  significant  invasion  occurred 
under the experimental conditions used, while at lower con- 
centration  (2.5/*g/filter)  the difference  in  invasiveness ob- 
served between the two cell lines was less pronounced(three- 
fold higher for IL~, cells compared with I.~).  Using collagen 
IV-coated  filters  (5/*g/filter),  which  promotes  cell  adher- 
ence but does not constitute  a  physical barrier to invasion, 
both cell lines  exhibited  a  comparable migration potential. 
L,,  invasion through a  25-#g matrigel-coated filter was in- 
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Figure 7. Regulation of u-PA mRNA in transfected mouse L cells. 
mRNA prepared from 24-h cultures of nontreated or treated trans- 
fected mouse L cells was assessed by Northern blot analysis. Rela- 
tive changes of u-PA mRNA were determined by hybridization to 
a random primer-labeled 600-bp Eco RI insert of the human u-PA 
cDNA. 4  #g of polyadenylated mRNA was applied per lane.  (a) 
Northern blot analysis of u-PA mRNA. (b) Changes in the relative 
intensity of the signals presented were quantified by densitometric 
analysis of the autoradiograms by assigning an arbitrary score of 
1 to the intensity of the mRNA signal obtained for nontreated, cos 
pUK0322-transfected  LupA cells.  Lanes 1-5 of the bar graph (b) 
correspond to lanes 1-5 ofa. (c) Ethidium bromide staining of total 
mRNA, which indicate similar loadings of mRNA for each sample. 
(Lane 0) Nontreated, pSVneo-transfected L,~o cells; (lane 1 ) non- 
treated,  cos  pUK0322-transfected  L.p^cells;  (lane  2)  L.pA cells 
treated with dexamethasone (500 nM);  (lane 3) L~p^ cells treated 
with cAMP (1 mM); (lane 4) L.m cells treated with pertussis toxin 
(5 nM); and (lane 5) L,p, cells treated with cholera toxin (50 nM). 
the amount of trypsin-sensitive material was observed when 
analyzing  ECM  cultured  with control  I.~ cells.  Collagen- 
ase  digestion  performed  under  similar  conditions  demon- 
strates a comparable degradation of the collagen substrate in 
all  three  conditions.  These  results  demonstrate  that  LP,- 
mediated  matrix  degradation  leads  to  solubilization  of the 
trypsin-sensitive  components,  while  the  collagen  compo- 
nents  are left unaltered. 
Basement Membrane Matrigei Invasion 
Fig.  13  a  demonstrates  the  ability  of Lu,,  cells  to  migrate 
through  various dilutions  of basement membrane matrigel. 
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Figure 8.  ECM degradation by HT-1080, l.~p^, and L~o cells.  (a) 
Cumulative  plot of the  total  radioactivity  solubilized  from R22 
smooth muscle cell  ECM  by HT-1080  (black bares),  I-~pA (grey 
boxes), and L,~o cells (white boxes). (b) Cumulative plot of PA ac- 
tivity released in supernatants by tumor cells in the course of matrix 
degradation.  (c) Corresponding cell counts at days  1-4 of tumor 
cells. 
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Figure 9. Modulation of ECM degradation by I~  cells with anti- 
u-PA IgG (a-uPA; 10 #g/ml), aprotinin (Apr; 200 U/ml), dexameth- 
asone (Dex; 500 nM), and dibutyryl cyclic AMP (cAMP; 1 mM). 
Grey boxes, treated cells; black box, control untreated cells (control 
for anti-u-PA IgGs were nonimmune IgGs at same concentration 
and, for all other conditions, culture medium without drug).  Re- 
suits are displayed as the percentage matrix breakdown obtained af- 
ter various tumor cell treatments relative to that of the control un- 
treated cells. All experiments were repeated twice and the standard 
deviations obtained were <10%. 
serine-proteases, such as plasmin and/or u-PA, played a ma- 
jor role in this invasive process (Fig.  13 b). 
Discussion 
To assess the potential role of pro-u-PA in the degradation 
and invasion of the ECM, we expressed the respective gene 
in mouse L cells. Restriction mapping demonstrated that cos 
pUK0322 contained the structral human pro-u-PA gene and 
at least 23 kb of 5' and  10 kb of 3' flanking sequence. The 
identity of the PA expressed by ~p, cells with human pro- 
u-PA was established by several independent criteria: antige- 
nicity and molecular weight characterization, as well as DFP 
resistance (Vassalli  et al.,  1984). The expression of pro-u- 
PA was stable over 10 passages. 
u-PA gene expression is known to be influenced by several 
hormones, protooncogene and oncogene products, and a va- 
riety of other effectors (Blasi et al., 1987). Human u-PA ex- 
pression by LP, cells was inhibited by dexamethasone. Such 
an effect  has previously been observed in HT-1080 cells (An- 
dreasen et al., 1986; Medcalfet al., 1986) and various breast 
carcinoma cell lines (Busso et al., 1987). Agonists of the ad- 
enylate cyclase pathway,  such as dibutyryl cyclic AMP, chol- 
era toxin, and pertussis toxin, induced u-PA expression in 
L~p, cells as shown in other cell systems (Mira-y-Lopez et 
al., 1983; Nagamine et al., 1983; Vassalli et al., 1976). The 
modulation of PA activity and mRNA was related to human 
and not to murine u-PA since: (a) zymography demonstrated 
human (54-kD) u-PA; and (b) murine u-PA mRNA did not 
hybridize under the conditions applied. Hence the regulation 
of u-PA  gene expression in  I.~,  cells  is  in  all  likelihood 
mediated by cis-acting regulatory elements present in the in- 
sert of cos pUK0322. 
Invasion is based on a series of complex interactions be- 
tween tumor cells and various types of ECM (Liotta et al., 
1984).  It involves: (a) attachment of cell surface receptors 
to  glycoproteins such  as  laminin,  fibronectin,  or  throm- 
bospondin; (b) protease activation and pericellular degrada- 
Figure 10. Thick thin sections from Epon-embedded material taken at day 1 (a and c) and 7 (b and d) from cultures of Ln~o (a and b) 
and L,pA (c and d) cells. The sections were cut at right angles to the plane of the culture dish. Bars,  10 #m. 
Cajot et al.  Urokinase-type  Plasminogen Activator and Cancer Invasion  921 Figure 11. Ultrastructural characterization by transmission  electron microscopy of tumor cell-mediated R22 matrix degradation. (a-c) HT- 
1080,  (d-f) L,~o, and (g-i) Lu~ cells all at days  1, 4,  and 7, respectively. Bars,  1 ~m. 
The Journal of Cell Biology, Volume 109, 1989  922 COLLAGENASE 
TRYPSIN 
0  20  40  60  80  100 
MATRIX  DEGRADATION  [%  of  control] 
Figure 12. Enzymatic digestion of residual R22 smooth muscle cell 
ECM after tumor cell coculture. ECM was incubated 4 d in the 
presence of L~r~ (hatched bars) and L~o cells (grey bars) or in ab- 
sence of  cells (black bars). The tumor cells were then lysed by incu- 
bation with 25 mM NH4OH, and the residual matrix was digested 
by sequential addition of 100 #g/ml trypsin and coilagenase. The 
resulting degradation obtained is expressed as the percentage of 
released radioactivity using tumor cell-cocultured ECM relative to 
ECM incubated in the absence of tumor ceils. 
communication). Recently, fine cytoplasmic extensions have 
been shown to express u-PA antigen in HT-1080 cells (P6lla- 
hen et al., 1988). Focal and/or extended areas of matrix-cell 
contacts are likely regions where degradative processes take 
place. 
Modulation of u-PA gene expression by dexamethasone or 
dibutyryl cyclic AMP demonstrated that the effect was cor- 
related with the potential of stimulated cells to degrade the 
ECM. Specific antibodies directed against human u-PA, as 
well as the serine protease inhibitor aprotinin, inhibited ma- 
trix degradation. This militates against a fibronectin-degrad- 
ing activity of u-PA, unaffected by aprotinin (Quigley et al., 
1987). Our results also bear on questions associated with the 
function of the u-PA receptor. Human u-PA does not bind to 
the  mouse receptor (Appella et al.,  1987;  Huarte et al., 
1987), hence such binding was not required for the increased 
potential of ~,, cells, described in the present study, to de- 
grade and/or invade the matrix. These results are in contrast 
with the recent demonstration by Ossowski (1988) of a role 
for the u-PA receptor in the invasion of the chick chorioallan- 
tion of matrix components; and (c) migration of cells within 
this matrix, u-PA has been reported to play an important role 
in protease-mediated matrix degradation (Dan0 et al., 1985; 
Saksela,  1985). It generates plasmin which in turn degrades 
glycoproteins such as fibronectin and laminin or it activates 
latent collagenases (Liotta et al.,  1981). 
L cells are particularly suited to the study of the effects of 
u-PA expression on the cell-matrix interaction because: (a) 
they do not express u-PA constitutively; (b) unlike HT-1080 
cells, they express only very little or no PA inhibitor (Panne- 
koek et al.,  1986; Rehemtulla et al.,  1987); and (c) murine 
u-PA receptor does not bind human u-PA (Appella et al., 
1987; Huarte et al.,  1987). Hence the protease effect per se 
can be studied without having to account for the modulating 
effect of u-PA receptor or PA inhibitor metabolism. We have 
demonstrated that I..~,,,, cells break down the ECM and, by 
quantitation of the release of radiolabeled products, shown 
that the degree of degradation is comparable with the one 
affected by human HT-1080 fibrosarcoma cells. Control L=o 
cells, which do not express endogenous PA, do not degrade 
such a model matrix. 
Morphologically, tumor cells contact the matrix surface by 
multiple pseudopodial extensions. In u-PA-expressing cells 
(HT-1080 and L~,), the electron density of amorphous ma- 
terial  of the  matrix  is  markedly  decreased.  Interestingly, 
fibrillar material  appears  largely resistant to degradation, 
suggesting a lack of collagenolytic and/or elastolytic activi- 
ties in  our experimental system. Jones et al.  (1979) have 
shown that R22 cells produce connective tissue proteins, in 
a cross-linked insoluble form, that remain anchored to the 
surface of the culture dish. By performing a sequential en- 
zyme digestion of the residual ECM obtained after culture 
with L,, tumor cells,  we demonstrated that partial diges- 
tion (25%) of the ECM had occurred and that the degrada- 
tion induced by L~,, cells affected essentially trypsin-sensi- 
tive constituents,  whereas  collagen components remained 
unaltered. These results are consistent with the observation 
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Figure 13. Basement membrane invasion assay. (a) Invasion of the 
artificial basement membrane by L~p^ (black boxes) or L~ cells 
(grey boxes).  The polycarbonate filters were coated with various 
matrigel concentrations ([•-3]  100, 25, or 12.5 #g/filter, respec- 
tively) or with collagen IV ([4]  5 #g/filter).  The results are ex- 
pressed as the number of  cells per field counted at the end of migra- 
tion. (b) Inhibition of basement membrane invasion by ~r~ cells 
in the presence of 200 klU/ml of  aprotinin (Apr) using filters coated 
with 25 #g of matrigel. 
Cajot et al. Urokinase-type Plasminogen Activator and Cancer Invasion  923 toic membrane by human tumor cells, suggesting that u-PA 
binding to its receptor was critical, in this particular invasion 
assay, for cell migration. Receptor binding may (a) concen- 
trate the activity and (b) localize proteolysis at critical sites 
of the cell surface. We present a model system suited for fur- 
ther investigation of the u-PA receptor: isolation of the hu- 
man uPA receptor gene and transfection into L~,A  cells would 
allow an analysis of its role in invasion and metastasis. 
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